Trading Signals: ADMS Stock Price Prediction and Forecast (Thu. Apr. 10, 2014 - Mon. Aug. 9, 2021)(Adamas Pharmaceuticals Inc)
| ADMS latest price $5.6050 (0.45%) ($5.6050 - $5.6050) on Wed. Jan. 27, 2021. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 4% (three month average) | RSI | 74 | Latest Price | $5.6050(0.45%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | ADMS advances 4.3% a day on average for past five trading days. | Weekly Trend | ADMS advances 5.5% a week on average for past two weeks. | Market Behavior | Broad based sell-off for large cap. Broad based sell-off for small cap. | Correlated ETFs | Broad market will support ADMS advance at 0% a week (0% probability) VCSH(34%) BND(27%) BWX(26%) VCIT(25%) BNDX(21%) | Factors Impacting ADMS price | ADMS will decline at least -2% in a week (0% probabilities). XOP(-21%) VXX(-20%) UUP(-20%) XLE(-18%) OIH(-18%) | Explanation | The rally is not sustainable and not supported by the broad market. | | | | | Relative Volatility | | | | Market Trend Strength | -2% (StdDev 4%) | Hourly BBV | 0.7 () | Intraday Trend | 0% | | | |
|
Inflection Point | Yes | 5 Day Moving Average | $5.09(10.12%) | 10 Day Moving Average | $4.82(16.29%) | 20 Day Moving Average | $4.69(19.51%) | To recent high | 0% | To recent low | 12.1% | Market Cap | $159m | | | | Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA. |